European Union: INSIGHT: Will Consent Be Disfavored As Basis For Processing Personal Data In Clinical Research Under EU Data Protection Law?

This article by Ropes & Gray partner Mark Barnes, associates Michael DiMaio and David Peloquin and Harvard Medical School professor Barbara Bierer, M.D. was published by Bloomberg Law on June 15, 2018.

The European General Data Protection Regulation ("GDPR"), which took effect on May 25, 2018, requires that all processing of personal data subject to the GDPR must have a legal basis under the GDPR's Article 6. To process special categories of personal data, which includes health and genetic data, data controllers must demonstrate an additional basis under Article 9. There has been concern that various European Union Member State research and/or data protection authorities may determine that they disfavor consent as the basis for processing data in the research context. Such an approach disfavoring consent may, however, present inconsistencies in the obligations faced by sponsors of clinical research both under U.S. law as well as potentially the law of various EU Member States.

If consent is not relied upon as the GDPR legal basis for processing (Art. 6), then the alternative bases presumably would be, for universities and public authorities, the "task carried out in the public interest" basis (Art. 6(1)(g)), and for commercial sponsors and charitable research organizations, the "legitimate interests" basis (Art. 6(1)(f)). Similarly, if consent is not the basis for processing special categories of personal data (often called "sensitive personal data" (Art. 9)) in clinical research, then research sponsors presumably would be forced to rely upon the processing "necessary for scientific purposes" basis under Article 9(2)(j). At least one EU Member State human research authority—the U.K. National Health Service's Health Research Administration ("NHS-HRA")—previously issued a guidance document suggesting that it disfavors consent as a basis for processing data in research. However, this NHS-HRA view would appear fundamentally inconsistent with previous guidance from the EU's Article 29 Working Party on Data Protection and Privacy, which recognized that gaining consent from subjects in clinical research has been the traditional approach, should continue, and could be reconciled with and incorporate consent for data processing. (Article 29 Working Party, Guidelines on Consent under Regulation 2016/679, pp. 27-28 (last modified April 10, 2018)). Similarly, the U.K. Information Commissioner's Office ("ICO") guide to consent as a basis for processing discusses rules on consent for scientific research purposes. Although the ICO does not require reliance upon consent as the basis for processing, it assumes that entities may rely upon consent as a basis for processing for scientific research, and identifies considerations for entities when doing so. (ICO, Lawful Basis for Processing: Consent). Furthermore, relying on consent for processing personal data in research has been an historical practice in the EU, as in other jurisdictions: since 1995, under the EU Data Protection Directive 95/46/EC, consent has been widely used for clinical research purposes as a basis for processing data and as a basis for transfer of personal data to jurisdictions that have not been found by the European Commission to have adequate data protection legislation.

A primary and understandable concern regarding using consent as a basis for processing personal data is the potential effect of data subjects' withdrawal of consent. Yet each data subject right carries with it appropriate exceptions to that right, and such exceptions ought to apply in the research context. For example, if a data subject withdraws consent on which the processing of the subject's personal data has been based, the data subject's ability to seek erasure of the data is available only when there is no other legal ground for the processing. (Art. 17(1)(b)). In the event of a data subject's withdrawal of consent, this would allow, for example, continued processing as necessary for scientific purposes, or if required for legal obligations, such as regulatory reporting to the U.S. Food and Drug Administration or European Medicines Agency. Indeed, the Article 29 Working Party Guidelines on Consent indicate that, "Controllers have an obligation to delete data that was processed on the basis of consent once that consent is withdrawn, assuming that there is no other purpose justifying the continued retention.... In that case, the other purpose justifying the processing must have its own separate legal basis. This does not mean the controller can swap from consent to another lawful basis." (p. 22, f.n. 54) (emphasis added). One reasonable argument here would be that although a controller cannot "swap" one legal basis for processing for another, nevertheless, when a data subject enrolled in clinical research withdraws his or her consent for processing, then the data subject has fundamentally changed his or her legal relationship to the trial site and the trial sponsor. In that case, the data subject has moved from the status of research participant to that of a person not participating in research but whose data are, from a regulatory and scientific viewpoint, required to be retained and processed for regulatory and scientific purposes. Therefore, processing their data could be based on "legitimate interest" (Art. 6(1)(f)). Additionally, processing their "special categories" of personal data can be based on necessity in the "area of public health, such as ... ensuring high standards of quality and safety of health care and of medicinal products or medical devices." (Art. 9(2)(i)). This is not the controller "swapping" bases for data processing, but rather, the data subject, through his or her voluntary choice to withdraw from the research, fundamentally altering his or her own legal relationships to the site and sponsor.

Unfortunately, EU Member State law related to processing personal data for research remains unsettled and ambiguous. Article 9(2)(j) allows processing of special categories of data when necessary for archiving purposes in the public interest, scientific or historical research purposes, or statistical purposes in accordance with Article 89(1) based on EU or Member State law. Article 89(1) in turn authorizes individual EU Member States to introduce technical and organizational safeguards for scientific research, and Article 89(2) authorizes derogations related to certain data subject rights. (Art. 89(1)-(2); Recital 156). However, because many EU Member States have not yet further specified these derogations, and because even those that have specified some derogations may not have done so comprehensively in regard to clinical research, reliance on Article 9(2)(j) presents problems for both industry and academic research sponsors.

In addition, a position that rejects consent as a basis for data processing in research potentially conflicts with U.S. and EU Member State law. In the U.S., Common Rule and FDA regulations require that informed consent forms contain a statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained. (45 C.F.R. § 46.116(5); 21 C.F.R. § 50.25(5)). Thus, research subjects already must consent to the processing of their personal data, and sponsors and researchers are required to include related operative language in the informed consent forms. Yet if consent is rejected as a basis for personal data processing in research, this required research consent would not be coterminous with consent to personal data processing for purposes of the GDPR. This presents a confusing situation for sponsors, researchers, and research subjects. Moreover, individual EU Member States are still developing national laws and regulations implementing the GDPR. To the extent that one or more EU Member States may disallow consent to be used under the GDPR as a basis for personal data processing, trial sponsors will be required to rely upon different bases for processing depending on the country of collection, presenting administrative hurdles and high transaction costs for clinical research in the EU—the situation that the GDPR was intended to prevent through standardization of approaches across the EU Member States.

It remains to be seen whether regulatory hostility toward the consent process as a basis for personal data processing will be adopted by research and data protection authorities in EU Member States. Industry and academic sponsors of research should carefully monitor further guidance on consent to processing under the GDPR and adjust their practices and legal documents accordingly.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions